Luciana Mendonça Barbosa

Luciana Mendonça Barbosa

Auto-generated profile, based on publicly available information

Luciana Mendonça Barbosa

Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
Rogério Adas Ayres de OliveiraRogério Adas Ayres de Oliveira
Rogério Adas Ayres de Oliveira
ABAbrahão Baptista
Abrahão Baptista
KSKatia Nunes Sá
Katia Nunes Sá
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
ONOsvaldo José Moreira Do Nascimento
Osvaldo José Moreira Do Nascimento
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
Background: Central neuropathic pain (CNP) is often refractory to available therapeutic strategies and there are few evidence-based treatment options. Many patients with neuropathic pain are not diagnosed or treated properly. Thus, consensus-based recommendations, adapted to the available drugs in the country, are necessary to guide clinical decisions. Objective: To develop recommendations for the treatment of CNP in Brazil. Methods: Systematic review, meta-analysis, and specialists opinions considering efficacy, adverse events profile, cost, and drug availability in public health. Results: Forty-four studies on CNP treatment were found, 20 were included in the qualitative analysis, and 15 in the quantitative analysis. Medications were classified as first-, second-, and third-line treatment based on systematic review, meta-analysis, and expert opinion. As first-line treatment, gabapentin, duloxetine, and tricyclic antidepressants were included. As second-line, venlafaxine, pregabalin for CND secondary to spinal cord injury, lamotrigine for CNP after stroke, and, in association with first-line drugs, weak opioids, in particular tramadol. For refractory patients, strong opioids (methadone and oxycodone), cannabidiol/delta-9-tetrahydrocannabinol, were classified as third-line of treatment, in combination with first or second-line drugs and, for central nervous system (CNS) in multiple sclerosis, dronabinol. Conclusions: Studies that address the treatment of CNS are scarce and heterogeneous, and a significant part of the recommendations is based on experts opinions. The CNP approach must be individualized, taking into account the availability of medication, the profile of adverse effects, including addiction risk, and patients' comorbidities.

4 August 2021 in Pain
Verified
Journal Article
Closed access
MLMarcelo Delboni Lemos
Marcelo Delboni Lemos
IFIsabelle Faillenot
Isabelle Faillenot
LLLeandro Tavares Lucato
Leandro Tavares Lucato
MTManoel Jacobsen Teixeira
Manoel Jacobsen Teixeira
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
Poststroke pain (PSP) is a heterogeneous term encompassing both central neuropathic (ie, central poststroke pain [CPSP]) and nonneuropathic poststroke pain (CNNP) syndromes. Central poststroke pain is classically related to damage in the lateral brainstem, posterior thalamus, and parietoinsular areas, whereas the role of white matter connecting these structures is frequently ignored. In addition, the relationship between stroke topography and CNNP is not completely understood. In this study, we address these issues comparing stroke location in a CPSP group of 35 patients with 2 control groups: 27 patients with CNNP and 27 patients with stroke without pain. Brain MRI images were analyzed by 2 complementary approaches: an exploratory analysis using voxel-wise lesion symptom mapping, to detect significant voxels damaged in CPSP across the whole brain, and a hypothesis-driven, region of interest–based analysis, to replicate previously reported sites involved in CPSP. Odds ratio maps were also calculated to demonstrate the risk for CPSP in each damaged voxel. Our exploratory analysis showed that, besides known thalamic and parietoinsular areas, significant voxels carrying a high risk for CPSP were located in the white matter encompassing thalamoinsular connections (one-tailed threshold Z > 3.96, corrected P value <0.05, odds ratio = 39.7). These results show that the interruption of thalamocortical white matter connections is an important component of CPSP, which is in contrast with findings from nonneuropathic PSP and from strokes without pain. These data can aid in the selection of patients at risk to develop CPSP who could be candidates to pre-emptive or therapeutic interventions.

17 July 2024 in Neurophysiologie Clinique
Verified
Journal Article
Open access
VBVictor Rossetto Barboza
Victor Rossetto Barboza
GKGabriel Taricani Kubota
Gabriel Taricani Kubota
Valquiria A SilvaValquiria A Silva
Valquiria A Silva
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
DADebora Arnaut
Debora Arnaut
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
Altered somatosensory processing in the posterior insula may play a role in chronic pain development and contribute to Parkinson disease (PD)-related pain. Posterior-superior insula (PSI) repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to have analgesic effects among patients with some chronic pain conditions. This study aimed at assessing the efficacy of PSI-rTMS for treating PD-related pain. This was a double-blinded, randomized, sham-controlled, parallel-arm trial (NCT03504748). People with PD (PwP)-related chronic pain underwent five daily PSI-rTMS sessions for a week, followed by once weekly maintenance stimulations for seven weeks. rTMS was delivered at 10 Hz and 80% of the resting motor threshold. The primary outcome was a ≥ 30% pain intensity reduction at 8 weeks compared to baseline. Functionality, mood, cognitive, motor status, and somatosensory thresholds were also assessed. Twenty-five patients were enrolled. Mean age was 55.2 ± 9.5 years-old, and 56% were female. Nociceptive pain accounted for 60%, and neuropathic and nociplastic for 20% each. No significant difference was found for 30% pain reduction response rates between active (42.7%) and sham groups (14.6%, p = 0.26). Secondary clinical outcomes and sensory thresholds also did not differ significantly. In a post hoc analysis, PwP with nociceptive pain sub-type experienced more pain relief after active (85.7%) compared to sham PSI-rTMS (25%, p = 0.032). Our preliminary results suggest that different types of PD-related pain may respond differently to treatment, and therefore people with PD may benefit from having PD-related pain well characterized in research trials and in clinical practice.

21 February 2023 in Neurophysiologie Clinique
Verified
Journal Article
Open access
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
FVFernanda Valerio
Fernanda Valerio
Valquiria A SilvaValquiria A Silva
Valquiria A Silva
ARAntônia Lilian de Lima Rodrigues
Antônia Lilian de Lima Rodrigues
RGRicardo Galhardoni
Ricardo Galhardoni
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
Central neuropathic pain (CNP) is associated with altered corticomotor excitability (CE), which can potentially provide insights into its mechanisms. The objective of this study is to describe the CE changes that are specifically related to CNP. We evaluated CNP associated with brain injury after stroke or spinal cord injury (SCI) due to neuromyelitis optica through a battery of CE measurements and comprehensive pain, neurological, functional, and quality of life assessments. CNP was compared to two groups of patients with the same disease: i. with non-neuropathic pain and ii. without chronic pain, matched by sex and lesion location. We included 163 patients (stroke=93; SCI=70: 74 had CNP, 43 had non-neuropathic pain, and 46 were pain-free). Stroke patients with CNP had lower motor evoked potential (MEP) in both affected and unaffected hemispheres compared to non- neuropathic pain and no-pain patients. Patients with CNP had lower amplitudes of MEPs (366 μV ±464 μV) than non-neuropathic (478 ±489) and no-pain (765 μV ± 880 μV) patients, p < 0.001. Short-interval intracortical inhibition (SICI) was defective (less inhibited) in patients with CNP (2.6±11.6) compared to no-pain (0.8±0.7), p = 0.021. MEPs negatively correlated with mechanical and cold-induced allodynia. Furthermore, classifying patients' results according to normative data revealed that at least 75% of patients had abnormalities in some CE parameters and confirmed MEP findings based on group analyses. CNP is associated with decreased MEPs and SICI compared to non-neuropathic pain and no-pain patients. Corticomotor excitability changes may be helpful as neurophysiological markers of the development and persistence of pain after CNS injury, as they are likely to provide insights into global CE plasticity changes occurring after CNS lesions associated with CNP.

24 February 2023 in European Journal of Neurology
Verified
Journal Article
Open access
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
FVFernanda Valerio
Fernanda Valerio
SPSamira Luisa Apóstolos Pereira
Samira Luisa Apóstolos Pereira
VSValquíria Aparecida da Silva
Valquíria Aparecida da Silva
ARAntônia Lilian de Lima Rodrigues
Antônia Lilian de Lima Rodrigues
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
Background: It is unknown if different etiologies or lesion topographies influence central neuropathic pain (CNP) clinical manifestation.Methods: We explored the symptom–somatosensory profile relationships in CNP patients with different types of lesions to the central nervous system to gain insight into CNP mechanisms. We compared the CNP profile through pain descriptors, standardized bedside examination, and quantitative sensory test in two different etiologies with segregated lesion locations: the brain, central poststroke pain (CPSP, n = 39), and the spinal cord central pain due to spinal cord injury (CPSCI, n = 40) in neuromyelitis optica.Results: Results are expressed as median (25th to 75th percentiles). CPSP presented higher evoked and paroxysmal pain scores compared to CPSCI (p < 0.001), and lower cold thermal limen (5.6°C [0.0–12.9]) compared to CPSCI (20.0°C [4.2–22.9]; p = 0.004). CPSCI also had higher mechanical pain thresholds (784.5 mN [255.0–1078.0]) compared to CPSP (235.2 mN [81.4–1078.0], p = 0.006) and higher mechanical detection threshold compared to control areas (2.7 [1.5–6.2] vs. 1.0 [1.0–3.3], p = 0.007). Evoked pain scores negatively correlated with mechanical pain thresholds (r = −0.38, p < 0.001) and wind‐up ratio (r = −0.57, p < 0.001).Conclusions: CNP of different etiologies may present different pain descriptors and somatosensory profiles, which is likely due to injury site differences within the neuroaxis. This information may help better design phenotype mechanism correlations and impact trial designs for the main etiologies of CNP, namely stroke and spinal cord lesions. This study provides evidence that topography may influence pain symptoms and sensory profile. The findings suggest that CNP mechanisms might vary according to pain etiology or lesion topography, impacting future mechanism‐based treatment choices.

18 July 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MLMarcelo Delboni Lemos
Marcelo Delboni Lemos
LBLuciana Mendonça Barbosa
Luciana Mendonça Barbosa
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
LLLeandro Tavares Lucato
Leandro Tavares Lucato
Background Central neuropathic poststroke pain (CNPSP) affects up to 12% of patients with stroke in general and up to 18% of patients with sensory deficits. This pain syndrome is often incapacitating and refractory to treatment. Brain computed tomography and magnetic resonance imaging (MRI) are widely used methods in the evaluation of CNPSP. Objective The present study aims to review the role of neuroimaging methods in CNPSP. Methods We performed a literature review of the main clinical aspects of CNPSP and the contribution of neuroimaging methods to study its pathophysiology, commonly damaged brain sites, and possible differential diagnoses. Lastly, we briefly mention how neuroimaging can contribute to the non-pharmacological CNPSP treatment. Additionally, we used a series of MRI from our institution to illustrate this review. Results Imaging has been used to explain CNPSP pathogenesis based on spinothalamic pathway damage and connectome dysfunction. Imaging locations associated with CNPSP include the brainstem (mainly the dorsolateral medulla), thalamus (especially the ventral posterolateral/ventral posteromedial nuclei), cortical areas such as the posterior insula and the parietal operculum, and, more recently, the thalamocortical white matter in the posterior limb of the internal capsule. Imaging also brings the prospect of helping search for new targets for non-pharmacological treatments for CNPSP. Other neuropathic pain causes identified by imaging include syringomyelia, multiple sclerosis, and herniated intervertebral disc. Conclusion Imaging is a valuable tool in the complimentary evaluation of CNPSP patients in clinical and research scenarios.